## Edgar Filing: Aeglea BioTherapeutics, Inc. - Form 4

•	Therapeutics, Inc.									
Form 4	16									
May 19, 20										
FORM	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Sectio of the Investment Company Act of 1940						PPROVAL 3235-0287			
Check t if no lou subject Section Form 4 Form 5 obligati may con <i>See</i> Inst 1(b).						Expires: January 31 2005 Estimated average burden hours per response 0.5				
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Lowe David George			2. Issuer Name <b>and</b> Ticker or Trading Symbol Aeglea BioTherapeutics, Inc. [AGLE]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
				of Earliest Tr Day/Year) 2016	ransaction		X Director X Officer (giv below) CE		% Owner her (specify t	
				. If Amendment, Date Original iled(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
AUSTIN, 7	ТХ 78746						Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	Acquired, Disposed of	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if		nAcquired Disposed (Instr. 3, 4	(A) or of (D)	Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
Reminder: Re	port on a separate lin	e for each cl	lass of sec	urities benef	ficially own	ned directly	or indirectly			
	For on a separate in				Perso inforn	ns who re nation con	spond to the collection to the collection to the collection to the collection to the form the collection of the form the collection to the form the collection to the collecti	are not	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

displays a currently valid OMB control

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Employee Stock Option (right to buy)	\$ 7.28	05/17/2016		A	160,000	<u>(1)</u>	05/16/2026	Common Stock	160,00

## Edgar Filing: Aeglea BioTherapeutics, Inc. - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Lowe David George C/O AEGLEA BIOTHERAPEUTICS, INC. 901 S. MOPAC EXPRESSWAY, SUITE 250 AUSTIN, TX 78746	Х		CEO and President			
Signatures						
/s/ Charles N. York II, by power of attorney	05/19/2016					
**Signature of Reporting Person	Date	•				
Explanation of Dechanges						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option vests and becomes exercisable in 48 equal monthly installments beginning on June 17, 2016, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.